在患有差差分化胰腺腺癌的患者中,辅助治疗的最佳时间
Mihir M Shah1,2, Parit T Mavani3, Subir Goyal4
1Division of Surgical Oncology, Department of Surgery, MedStar Georgetown Lombardi Cancer Center, Washington, DC, USA. Mihir.m.shah@medstar.net.
Annals of surgical oncology
|February 16, 2026
概括
对于差分化的胰腺癌患者,在手术后9周内开始辅助化疗可以改善整体生存率. 学术机构可能需要优化流程,以便在胰腺管道腺癌切除后及时治疗.
科学领域:
- 瘤学 在瘤学方面.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 胰腺管腺癌 (PDAC) 治疗包括多模式治疗,包括化疗和手术.
- 差异化的PDAC与生存率的降低有关,原因是手术后不清楚最佳治疗时间.
- 手术后恢复预期的瘤治疗 (RIOT) 时间对于患者的治疗结果至关重要.
研究的目的:
- 评估辅助化疗时间与差异化PDAC患者的整体存活率 (OS) 之间的关联.
- 评估恢复预期瘤治疗 (RIOT) 的时间如何影响PDAC手术后的生存率.
- 确定影响PDAC患者RIOT时间的因素.
主要方法:
- 利用国家癌症数据库 (2007-2016) 对接受手术和辅助化疗的差异化,非转移性PDAC患者.
- 员工调整了考克斯的比例危险模型,以基于RIOT时间 (在9周内与9周后) 来分析OS.
- 使用后勤回归来确定与在9周内实现RIOT相关的因素.
主要成果:
- 在2737名患者中,66.1%的患者在手术后9周内接受辅助化疗.
- 在9周内进行辅助化疗与显著改善的OS相关 (aHR为0.90,p=0.03).
- 在学术机构接受治疗与在9周内接受化疗的几率较低有关 (aOR 0.83,p=0.03).
结论:
- 在手术后9周内开始的辅助疗法可能有利于患有差异化PDAC的患者.
- 学术中心有机会改善PDAC切除后辅助化疗的及时性.
- 优化RIOT时间对于提高PDAC患者的生存率至关重要.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
388
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
388
01:30Acute Pancreatitis II: Clinical Manifestations and Management
900
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
900